Purpura, Thrombocytopaenic, Idiopathic Clinical Trial
Official title:
An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers With Mild, Moderate or Severe Hepatic Impairment
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00908037 -
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
Completed |
NCT00442871 -
Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment
|
Phase 1 | |
Completed |
NCT01098487 -
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
Phase 4 | |
Withdrawn |
NCT01440361 -
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
|
Phase 2 | |
Completed |
NCT01064336 -
Promacta Pregnancy Registry
|
N/A | |
Completed |
NCT00424177 -
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
|
Phase 2 | |
Completed |
NCT00351468 -
EXTEND (Eltrombopag Extended Dosing Study)
|
Phase 3 | |
Completed |
NCT00688272 -
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
|
Phase 1 | |
Completed |
NCT01072162 -
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect
|
Phase 1 | |
Completed |
NCT00643929 -
LENS - Long-term Eltrombopag Observational Study
|
N/A | |
Completed |
NCT00102739 -
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
Completed |
NCT01416311 -
Drug Use Investigation for REVOLADE (ITP)
|